BMC Nephrology Nephrology

Comparative effectiveness of darbepoetin vs other agents in chronic kidney disease-related anemia: a systematic review and network meta-analysis

Muhammad Faique Hassan, Muhammad Shaheer Bin Faheem, Shamikha Cheema, Fathimathul Henna, Saman Javid, M. Rafiqul Islam, Insha Habib, Muhammad Usman, Yousif Hameed Kurmasha, Sumaya Samadi, Yaqub Nadeem Mohammad
Springer Nature · 2025-11-17 · DOI 10.1186/s12882-025-04557-7

Abstract

Abstract Introduction In the advanced stages of chronic kidney disease (CKD), anemia impacts 78.9% to 96.5% of patients. Darbepoetin is utilized for the treatment of anemia associated with chronic kidney disease (CKD). The function of darbepoetin alfa can be clarified by comparing it with other agents. A comprehensive review and network meta-analysis were conducted to assess the safety and efficacy of Darbepoetin alfa compared to other agents in the treatment of anemia associated with chronic kidney disease (CKD). Methods A systematic review and network meta-analysis were conducted adhering to PRISMA-NMA guidelines. A systematic search was performed in databases Medline, Embase, and Scopus from inception to November 24, 2024, without language limitations. Randomized controlled trials assessing erythropoietin-stimulating agents (ESAs) or placebo in adults with chronic kidney disease (CKD)-related anemia were included. Data extraction and risk of bias assessment (RoB 2.0) were performed separately. Bayesian network meta-analysis using random-effects models was carried out using BUGSnet in R. Treatment effects were measured as odds ratios (ORs) or mean differences (MDs) with 95% credible intervals. Heterogeneity, inconsistency, and publication bias were evaluated, and certainty of evidence was assessed using the GRADE approach. Results In this network meta-analysis of 21 randomized trials involving over 4,000 CKD patients with anemia, Methoxy polyethylene glycol-epoetin beta showed the greatest hemoglobin increase, while Molidustat demonstrated the best cardiovascular and thrombotic safety despite lower efficacy. Daprodustat provided moderate hemoglobin improvement with a safety profile comparable to darbepoetin, showing no significant differences in mortality or cardiovascular events. Transferrin saturation, hypertension, and diabetes-related adverse events did not differ significantly across treatments. Roxadustat was associated with a higher incidence of gastrointestinal adverse events, particularly diarrhea. Conclusion Daprodustat and roxadustat indicated equivalent or higher efficacy when compared to darbepoetin in elevating hemoglobin levels in CKD-related anemia, with daprodustat demonstrating a good safety profile. While conventional ESAs remain beneficial, HIF-PHIs offer promising oral alternatives with possible benefits in cardiovascular safety and decreased hypertension risk. Further head-to-head trials are necessary to confirm these findings and guide individualized treatment strategies. Clinical trial number Not applicable.

Read at publisher →